Long COVID
Fluvoxamine eases severe fatigue in long COVID patients
An Ruwaito ta hanyar AI Hoton da AI ya samar
A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.
Researchers in Finland have found no evidence of widespread brain inflammation among people with long COVID. The findings instead link more severe symptoms to increased activity in brain regions involved in emotion and memory.
An Ruwaito ta hanyar AI An Binciki Gaskiya
A major randomized trial led by Mass General Brigham found that a four-week course of high-dose vitamin D3 started soon after a positive COVID-19 test did not reduce acute illness severity, healthcare visits or deaths, and did not curb household spread. But in an analysis limited to participants who consistently took the assigned pills, researchers observed a small, borderline statistically significant difference in lingering symptoms reported eight weeks after infection, a finding they say warrants further study.
A recent study published on October 2, 2025, indicates that COVID-19 vaccinations significantly lower the risk of developing long COVID. Researchers analyzed data from over 1 million patients, finding a 50% reduction in incidence among vaccinated individuals. The findings highlight ongoing benefits of vaccination even after the acute phase of infection.